Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 6—June 2005

Volume 11, Number 6—June 2005   PDF Version [PDF - 7.46 MB - 208 pages]

Perspective

  • An Emptying Quiver: Antimicrobial Drugs and Resistance PDF Version [PDF - 159 KB - 3 pages]
    J. Weber and P. Courvalin
            Cite This Article
    EID Weber J, Courvalin P. An Emptying Quiver: Antimicrobial Drugs and Resistance. Emerg Infect Dis. 2005;11(6):791-793. https://dx.doi.org/10.3201/eid1106.050471
    AMA Weber J, Courvalin P. An Emptying Quiver: Antimicrobial Drugs and Resistance. Emerging Infectious Diseases. 2005;11(6):791-793. doi:10.3201/eid1106.050471.
    APA Weber, J., & Courvalin, P. (2005). An Emptying Quiver: Antimicrobial Drugs and Resistance. Emerging Infectious Diseases, 11(6), 791-793. https://dx.doi.org/10.3201/eid1106.050471.
  • Antimicrobial Resistance Determinants and Future Control PDF Version [PDF - 280 KB - 8 pages]
    S. Harbarth and M. H. Samore
        View Abstract

    At the beginning of the 21st century, antimicrobial resistance is common, has developed against every class of antimicrobial drug, and appears to be spreading into new clinical niches. We describe determinants likely to influence the future epidemiology and health impact of antimicrobial-resistant infections. Understanding these factors will ultimately optimize preventive strategies for an unpredictable future.

        Cite This Article
    EID Harbarth S, Samore MH. Antimicrobial Resistance Determinants and Future Control. Emerg Infect Dis. 2005;11(6):794-801. https://dx.doi.org/10.3201/eid1106.050167
    AMA Harbarth S, Samore MH. Antimicrobial Resistance Determinants and Future Control. Emerging Infectious Diseases. 2005;11(6):794-801. doi:10.3201/eid1106.050167.
    APA Harbarth, S., & Samore, M. H. (2005). Antimicrobial Resistance Determinants and Future Control. Emerging Infectious Diseases, 11(6), 794-801. https://dx.doi.org/10.3201/eid1106.050167.
  • Hidden Epidemic of Macrolide-resistant Pneumococci PDF Version [PDF - 209 KB - 6 pages]
    K. P. Klugman and J. R. Lonks
        View Abstract

    Community-acquired respiratory tract infections (RTIs) account for a substantial proportion of outpatient antimicrobial drug prescriptions worldwide. Concern over the emergence of multidrug resistance in pneumococci has largely been focused on penicillin-resistant Streptococcus pneumoniae. Macrolide antimicrobial drugs have been widely used to empirically treat community-acquired RTIs because of their efficacy in treating both common and atypical respiratory pathogens, including S. pneumoniae. However, increased macrolide use has been associated with a global increase in pneumococcal resistance, which is leading to concern over the continued clinical efficacy of the macrolides to treat community-acquired RTIs. We provide an overview of macrolide-resistant S. pneumoniae and assess the impact of this resistance on the empiric treatment of community-acquired RTIs.

        Cite This Article
    EID Klugman KP, Lonks JR. Hidden Epidemic of Macrolide-resistant Pneumococci. Emerg Infect Dis. 2005;11(6):802-807. https://dx.doi.org/10.3201/eid1106.050147
    AMA Klugman KP, Lonks JR. Hidden Epidemic of Macrolide-resistant Pneumococci. Emerging Infectious Diseases. 2005;11(6):802-807. doi:10.3201/eid1106.050147.
    APA Klugman, K. P., & Lonks, J. R. (2005). Hidden Epidemic of Macrolide-resistant Pneumococci. Emerging Infectious Diseases, 11(6), 802-807. https://dx.doi.org/10.3201/eid1106.050147.

Research

  • Community-associated Methicillin-resistant Staphylococcus aureus in Hospital Nursery and Maternity Units PDF Version [PDF - 161 KB - 6 pages]
    S. Bratu et al.
        View Abstract

    Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has rarely been reported in the hospital setting. We report an outbreak of 7 cases of skin and soft tissue infections due to a strain of CA-MRSA. All patients were admitted to the labor and delivery, nursery, or maternity units during a 3-week period. Genetic fingerprinting showed that the outbreak strain was closely related to the USA 400 strain that includes the midwestern strain MW2. All isolates contained the staphylococcal chromosome cassette mec type IV. Genes for Panton-Valentine leukocidin and staphylococcal enterotoxin K were detected in all isolates, and most contained other enterotoxin genes. Testing of nearly 2,000 MRSA isolates collected during citywide surveillance studies from 1999 to 2003 showed that ≈1% were genetically related to MW2. CA-MRSA strain MW2 has been present in this region at least since 1999. This study documents the spread of this strain among healthy newborns at 1 hospital.

        Cite This Article
    EID Bratu S, Eramo A, Kopec R, Coughlin E, Ghitan M, Yost R, et al. Community-associated Methicillin-resistant Staphylococcus aureus in Hospital Nursery and Maternity Units. Emerg Infect Dis. 2005;11(6):808-813. https://dx.doi.org/10.3201/eid1106.040885
    AMA Bratu S, Eramo A, Kopec R, et al. Community-associated Methicillin-resistant Staphylococcus aureus in Hospital Nursery and Maternity Units. Emerging Infectious Diseases. 2005;11(6):808-813. doi:10.3201/eid1106.040885.
    APA Bratu, S., Eramo, A., Kopec, R., Coughlin, E., Ghitan, M., Yost, R....Quale, J. (2005). Community-associated Methicillin-resistant Staphylococcus aureus in Hospital Nursery and Maternity Units. Emerging Infectious Diseases, 11(6), 808-813. https://dx.doi.org/10.3201/eid1106.040885.
  • Relative Fitness of Fluoroquinolone-resistant Streptococcus pneumoniae PDF Version [PDF - 191 KB - 7 pages]
    C. N. Johnson et al.
        View Abstract

    Fluoroquinolone resistance in Streptococcus pneumoniae is primarily mediated by point mutations in the quinolone resistance–determining regions of gyrA and parC. Antimicrobial resistance mutations in housekeeping genes often decrease fitness of microorganisms. To investigate the fitness of quinolone-resistant S. pneumoniae (QRSP), the relative growth efficiencies of 2 isogenic QRSP double mutants were compared with that of their fluoroquinolone-susceptible parent, EF3030, by using murine nasopharyngeal colonization and pneumonia models. Strains containing the GyrA: Ser81Phe, ParC: Ser79Phe double mutations, which are frequently seen in clinical QRSP, competed poorly with EF3030 in competitive colonization or competitive lung infections. However, they efficiently produced lung infection even in the absence of EF3030. The strain containing the GyrA: Ser81Phe, ParC: Ser79Tyr double mutations, which is seen more frequently in laboratory-derived QRSP than in clinical QRSP, demonstrated reduced nasal colonization in competitive or noncompetitive lung infections. However, the strain was equally able to cause competitive or noncompetitive lung infections as well as EF3030.

        Cite This Article
    EID Johnson CN, Briles DE, Benjamin WH, Hollingshead SK, Waites KB. Relative Fitness of Fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis. 2005;11(6):814-820. https://dx.doi.org/10.3201/eid1106.040840
    AMA Johnson CN, Briles DE, Benjamin WH, et al. Relative Fitness of Fluoroquinolone-resistant Streptococcus pneumoniae. Emerging Infectious Diseases. 2005;11(6):814-820. doi:10.3201/eid1106.040840.
    APA Johnson, C. N., Briles, D. E., Benjamin, W. H., Hollingshead, S. K., & Waites, K. B. (2005). Relative Fitness of Fluoroquinolone-resistant Streptococcus pneumoniae. Emerging Infectious Diseases, 11(6), 814-820. https://dx.doi.org/10.3201/eid1106.040840.
  • Global Spread of Vancomycin-resistant Enterococcus faecium from Distinct Nosocomial Genetic Complex PDF Version [PDF - 316 KB - 8 pages]
    R. Willems et al.
        View Abstract

    Vancomycin-resistant enterococci (VRE) have caused hospital outbreaks worldwide, and the vancomycin-resistance gene (vanA) has crossed genus boundaries to methicillin-resistant Staphylococcus aureus. Spread of VRE, therefore, represents an immediate threat for patient care and creates a reservoir of mobile resistance genes for other, more virulent pathogens. Evolutionary genetics, population structure, and geographic distribution of 411 VRE and vancomycin-susceptible Enterococcus faecium isolates, recovered from human and nonhuman sources and community and hospital reservoirs in 5 continents, identified a genetic lineage of E. faecium (complex-17) that has spread globally. This lineage is characterized by 1) ampicillin resistance, 2) a pathogenicity island, and 3) an association with hospital outbreaks. Complex-17 is an example of cumulative evolutionary processes that improved the relative fitness of bacteria in hospital environments. Preventing further spread of this epidemic E. faecium subpopulation is critical, and efforts should focus on the early disclosure of ampicillin-resistant complex-17 strains.

        Cite This Article
    EID Willems R, Top J, van Santen M, Robinson D, Coque TM, Baquero F, et al. Global Spread of Vancomycin-resistant Enterococcus faecium from Distinct Nosocomial Genetic Complex. Emerg Infect Dis. 2005;11(6):821-828. https://dx.doi.org/10.3201/eid1106.041204
    AMA Willems R, Top J, van Santen M, et al. Global Spread of Vancomycin-resistant Enterococcus faecium from Distinct Nosocomial Genetic Complex. Emerging Infectious Diseases. 2005;11(6):821-828. doi:10.3201/eid1106.041204.
    APA Willems, R., Top, J., van Santen, M., Robinson, D., Coque, T. M., Baquero, F....Bonten, M. (2005). Global Spread of Vancomycin-resistant Enterococcus faecium from Distinct Nosocomial Genetic Complex. Emerging Infectious Diseases, 11(6), 821-828. https://dx.doi.org/10.3201/eid1106.041204.
  • Community Prescribing and Resistant Streptococcus pneumoniae PDF Version [PDF - 425 KB - 9 pages]
    G. Barkai et al.
        View Abstract

    We investigated the association between prescribing antimicrobial agents and antimicrobial resistance of Streptococcus pneumoniae among children with acute otitis media in southern Israel. During a 6-year period, all prescriptions of a sample of ≈20% of Jewish and Bedouin children <5 years of age were recorded and all pneumococcal isolates from middle ear fluid were collected. Although antimicrobial drug use was significantly higher in Bedouin children, the proportion of S. pneumoniae isolates with penicillin MIC ≥1.0 μg/mL was significantly higher in Jewish children. In both populations, antimicrobial prescriptions were markedly reduced over time, especially for penicillins and erythromycin. In contrast, azithromycin prescriptions increased from 1998 to 2001 with a parallel increase in macrolide and multidrug resistance. Penicillin resistance was associated with macrolide resistance. These findings strongly suggest that azithromycin affects increased antimicrobial resistance, including multidrug resistance, in S. pneumoniae.

        Cite This Article
    EID Barkai G, Greenberg D, Givon-Lavi N, Dreifuss E, Vardy D, Dagan R, et al. Community Prescribing and Resistant Streptococcus pneumoniae. Emerg Infect Dis. 2005;11(6):829-837. https://dx.doi.org/10.3201/eid1106.050198
    AMA Barkai G, Greenberg D, Givon-Lavi N, et al. Community Prescribing and Resistant Streptococcus pneumoniae. Emerging Infectious Diseases. 2005;11(6):829-837. doi:10.3201/eid1106.050198.
    APA Barkai, G., Greenberg, D., Givon-Lavi, N., Dreifuss, E., Vardy, D., & Dagan, R. (2005). Community Prescribing and Resistant Streptococcus pneumoniae. Emerging Infectious Diseases, 11(6), 829-837. https://dx.doi.org/10.3201/eid1106.050198.
  • pVir and Bloody Diarrhea in Campylobacter jejuni Enteritis PDF Version [PDF - 68 KB - 5 pages]
    D. M. Tracz et al.
        View Abstract

    The plasmid pVir may play a role in the virulence of Campylobacter jejuni, a leading cause of bacterial gastroenteritis. The pVir plasmid was identified in 17% of 104 C. jejuni clinical isolates studied and was significantly associated with the occurrence of blood in patient stool, a marker of invasive infection. The pVir plasmid was not associated with greater occurrence of diarrhea, fever, pain, vomiting, or need for patient hospitalization. Isolates containing pVir were also associated with the presence of a tetracycline-resistance plasmid, but pVir did not transfer with tetracycline-resistance plasmids to recipient strains of C. jejuni. The association of pVir and bloody stool suggests that pVir may be clinically relevant in C. jejuni infections.

        Cite This Article
    EID Tracz DM, Keelan M, Ahmed-Bentley J, Gibreel A, Kowalewska-Grochowska K, Taylor DE, et al. pVir and Bloody Diarrhea in Campylobacter jejuni Enteritis. Emerg Infect Dis. 2005;11(6):839-843. https://dx.doi.org/10.3201/eid1106.041052
    AMA Tracz DM, Keelan M, Ahmed-Bentley J, et al. pVir and Bloody Diarrhea in Campylobacter jejuni Enteritis. Emerging Infectious Diseases. 2005;11(6):839-843. doi:10.3201/eid1106.041052.
    APA Tracz, D. M., Keelan, M., Ahmed-Bentley, J., Gibreel, A., Kowalewska-Grochowska, K., & Taylor, D. E. (2005). pVir and Bloody Diarrhea in Campylobacter jejuni Enteritis. Emerging Infectious Diseases, 11(6), 839-843. https://dx.doi.org/10.3201/eid1106.041052.
  • Community-associated Methicillin-resistant Staphylococcus aureus, Canada PDF Version [PDF - 208 KB - 7 pages]
    M. R. Mulvey et al.
        View Abstract

    A total of 184 methicillin-resistant Staphylococcus aureus (MRSA) strains were collected from patients who sought treatment primarily for skin and soft tissue infections from January 1, 1999, to March 31, 2002, in east-central Saskatchewan, Canada. Molecular subtyping analysis using pulsed-field gel electrophoresis showed 2 major clusters. Cluster A (n = 55) was composed of a multidrug-resistant MRSA strain associated with a long-term care facility and was similar to the previously reported nosocomial Canadian epidemic strain labeled CMRSA-2. Cluster B (n = 125) was associated with cases identified at community health centers and was indistinguishable from a community-associated (CA)-MRSA strain identified previously in the United States (USA400). Cluster B remained susceptible to a number of classes of antimicrobial agents and harbored the lukF-PV and lukS-PV toxin genes. Over 50% of both clonal groups displayed high-level resistance to mupirocin. This is the first report of the USA400 strain harboring the lukF-PV and lukS-PV toxin genes in Canada.

        Cite This Article
    EID Mulvey MR, MacDougall L, Cholin B, Horsman G, Fidyk M, Woods S, et al. Community-associated Methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis. 2005;11(6):844-850. https://dx.doi.org/10.3201/eid1106.041146
    AMA Mulvey MR, MacDougall L, Cholin B, et al. Community-associated Methicillin-resistant Staphylococcus aureus, Canada. Emerging Infectious Diseases. 2005;11(6):844-850. doi:10.3201/eid1106.041146.
    APA Mulvey, M. R., MacDougall, L., Cholin, B., Horsman, G., Fidyk, M., & Woods, S. (2005). Community-associated Methicillin-resistant Staphylococcus aureus, Canada. Emerging Infectious Diseases, 11(6), 844-850. https://dx.doi.org/10.3201/eid1106.041146.
  • Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance PDF Version [PDF - 322 KB - 8 pages]
    D. J. Farrell et al.
        View Abstract

    Streptococcus pneumoniae isolates (N = 31,001) were collected from patients with community-acquired respiratory tract infections during the PROTEKT US surveillance study (2000–2003). While the macrolide (erythromycin) resistance rate remained stable at ≈29%, the prevalence of resistant isolates containing both erm(B) and mef(A) increased from 9.7% in year 1 to 16.4% in year 3, with substantial regional variability. Almost all (99.2%) dual erm(B)+mef(A) macrolide-resistant isolates exhibited multidrug resistance, whereas 98.6% and 99.0% were levofloxacin- and telithromycin-susceptible, respectively. These strains were most commonly isolated from the ear or middle-ear fluid of children. Of 152 representative erm(B)+mef(A) isolates, >90% were clonally related to the multidrug-resistant international Taiwan19F-14 clonal complex 271 (CC271). Of 366 erm(B)+mef(A) isolates from the PROTEKT global study (1999–2003), 83.3% were CC271, with the highest prevalence seen in South Africa, South Korea, and the United States. This study confirms the increasing global emergence and rapidly increasing US prevalence of this multidrug-resistant pneumococcal clone.

        Cite This Article
    EID Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP, et al. Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance. Emerg Infect Dis. 2005;11(6):851-858. https://dx.doi.org/10.3201/eid1106.050222
    AMA Farrell DJ, Jenkins SG, Brown SD, et al. Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance. Emerging Infectious Diseases. 2005;11(6):851-858. doi:10.3201/eid1106.050222.
    APA Farrell, D. J., Jenkins, S. G., Brown, S. D., Patel, M., Lavin, B. S., & Klugman, K. P. (2005). Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance. Emerging Infectious Diseases, 11(6), 851-858. https://dx.doi.org/10.3201/eid1106.050222.
  • International Salmonella Typhimurium DT104 Infections, 1992–2001 PDF Version [PDF - 371 KB - 9 pages]
    M. Helms et al.
        View Abstract

    The incidence of multidrug-resistant (MDR) Salmonella Typhimurium infections in humans, and in particular MDR definitive phage type 104 (DT104), has increased substantially in many countries in the last 2 decades, often associated with increased illness. To examine the magnitude of this problem, a survey was conducted among countries with available antimicrobial resistance or phage typing surveillance data. A total of 29, primarily industrialized, countries participated in the survey, which covered the years 1992–2001. Overall, the incidence of MDR S. Typhimurium and DT104 increased continuously during this period, although the problem affected primarily Europe and North America. The increase appeared to have peaked in the United Kingdom but not in other countries. Also, the incidence of quinolone-resistant S. Typhimurium was increasing. This survey implies that MDR S. Typhimurium constitutes an increasing public health problem in large parts of the world and emphasizes the importance of surveillance and control programs.

        Cite This Article
    EID Helms M, Ethelberg S, Mølbak K. International Salmonella Typhimurium DT104 Infections, 1992–2001. Emerg Infect Dis. 2005;11(6):859-867. https://dx.doi.org/10.3201/eid1106.041017
    AMA Helms M, Ethelberg S, Mølbak K. International Salmonella Typhimurium DT104 Infections, 1992–2001. Emerging Infectious Diseases. 2005;11(6):859-867. doi:10.3201/eid1106.041017.
    APA Helms, M., Ethelberg, S., & Mølbak, K. (2005). International Salmonella Typhimurium DT104 Infections, 1992–2001. Emerging Infectious Diseases, 11(6), 859-867. https://dx.doi.org/10.3201/eid1106.041017.
  • Methicillin-resistant–Staphylococcus aureus Hospitalizations, United States PDF Version [PDF - 174 KB - 5 pages]
    M. J. Kuehnert et al.
        View Abstract

    Methicillin-resistant Staphylococcus aureus (MRSA) is increasingly a cause of nosocomial and community-onset infection with unknown national scope and magnitude. We used the National Hospital Discharge Survey to calculate the number of US hospital discharges listing S. aureus–specific diagnoses, defined as those having at least 1 International Classification of Diseases (ICD)-9 code specific for S. aureus infection. The number of hospital discharges listing S. aureus-specific diagnoses was multiplied by the proportion of methicillin resistance for each corresponding infection site to determine the number of MRSA infections. From 1999 to 2000, an estimated 125,969 hospitalizations with a diagnosis of MRSA infection occurred annually, including 31,440 for septicemia, 29,823 for pneumonia, and 64,706 for other infections, accounting for 3.95 per 1,000 hospital discharges. The method used in our analysis may provide a simple way to assess trends of the magnitude of MRSA infection nationally.

        Cite This Article
    EID Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB, et al. Methicillin-resistant–Staphylococcus aureus Hospitalizations, United States. Emerg Infect Dis. 2005;11(6):868-872. https://dx.doi.org/10.3201/eid1106.040831
    AMA Kuehnert MJ, Hill HA, Kupronis BA, et al. Methicillin-resistant–Staphylococcus aureus Hospitalizations, United States. Emerging Infectious Diseases. 2005;11(6):868-872. doi:10.3201/eid1106.040831.
    APA Kuehnert, M. J., Hill, H. A., Kupronis, B. A., Tokars, J. I., Solomon, S. L., & Jernigan, D. B. (2005). Methicillin-resistant–Staphylococcus aureus Hospitalizations, United States. Emerging Infectious Diseases, 11(6), 868-872. https://dx.doi.org/10.3201/eid1106.040831.
  • Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs PDF Version [PDF - 609 KB - 10 pages]
    J. M. Stelling et al.
        View Abstract

    Collaboration between networks presents opportunities to increase analytical power and cross-validate findings. Multivariate analyses of 2 large, international datasets (MYSTIC and SENTRY) from the Global Advisory on Antibiotic Resistance Data program explored temporal, geographic, and demographic trends in Escherichia coli resistance from 1997 to 2001. Elevated rates of nonsusceptibility were seen in Latin America, southern Europe, and the western Pacific, and lower rates were seen in North America. For most antimicrobial drugs considered, nonsusceptibility was higher in isolates from men, older patients, and intensive care unit patients. Nonsusceptibility to ciprofloxacin was higher in younger patients, rose with time, and was not associated with intensive care unit status. In univariate analyses, estimates of nonsusceptibility from MYSTIC were consistently higher than those from SENTRY, but these differences disappeared in multivariate analyses, which supports the epidemiologic relevance of findings from the 2 programs, despite differences in surveillance strategies.

        Cite This Article
    EID Stelling JM, Travers K, Jones RN, Turner PJ, O'Brien TF, Levy SB, et al. Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs. Emerg Infect Dis. 2005;11(6):873-882. https://dx.doi.org/10.3201/eid1106.041160
    AMA Stelling JM, Travers K, Jones RN, et al. Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs. Emerging Infectious Diseases. 2005;11(6):873-882. doi:10.3201/eid1106.041160.
    APA Stelling, J. M., Travers, K., Jones, R. N., Turner, P. J., O'Brien, T. F., & Levy, S. B. (2005). Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs. Emerging Infectious Diseases, 11(6), 873-882. https://dx.doi.org/10.3201/eid1106.041160.
  • Nonprescribed Antimicrobial Drugs in Latino Community, South Carolina PDF Version [PDF - 88 KB - 6 pages]
    A. G. Mainous et al.
        View Abstract

    We investigated in a sample of Latinos the practices of antimicrobial drug importation and use of nonprescribed antimicrobial drugs. In interviews conducted with 219 adults, we assessed health beliefs and past and present behaviors consistent with acquiring antimicrobial drugs without a prescription in the United States. Many (30.6%) believed that antimicrobial drugs should be available in the United States without a prescription. Furthermore, 16.4% had transported nonprescribed antimicrobial drugs into the United States, and 19.2% had acquired antimicrobial agents in the United States without a prescription. A stepwise logistic regression analysis showed that the best predictors of having acquired nonprescribed antimicrobial drugs in the United States were beliefs and behavior consistent with limited regulations on such drugs. Many persons within the Latino community self-medicate with antimicrobial drugs obtained without a prescription both inside and outside the United States, which adds to the reservoir of antimicrobial drugs in the United States.

        Cite This Article
    EID Mainous AG, Cheng AY, Garr RC, Tilley BC, Everett CJ, McKee M, et al. Nonprescribed Antimicrobial Drugs in Latino Community, South Carolina. Emerg Infect Dis. 2005;11(6):883-888. https://dx.doi.org/10.3201/eid1106.040960
    AMA Mainous AG, Cheng AY, Garr RC, et al. Nonprescribed Antimicrobial Drugs in Latino Community, South Carolina. Emerging Infectious Diseases. 2005;11(6):883-888. doi:10.3201/eid1106.040960.
    APA Mainous, A. G., Cheng, A. Y., Garr, R. C., Tilley, B. C., Everett, C. J., & McKee, M. (2005). Nonprescribed Antimicrobial Drugs in Latino Community, South Carolina. Emerging Infectious Diseases, 11(6), 883-888. https://dx.doi.org/10.3201/eid1106.040960.
  • Fluoroquinolone-resistant Escherichia coli Carriage in Long-Term Care Facility PDF Version [PDF - 85 KB - 6 pages]
    J. N. Maslow et al.
        View Abstract

    We conducted a cross-sectional study to determine the prevalence of, and risk factors for, colonization with fluoroquinolone (FQ)-resistant Escherichia coli in residents in a long-term care facility. FQ-resistant E. coli were identified from rectal swabs for 25 (51%) of 49 participants at study entry. On multivariable analyses, prior FQ use was the only independent risk factor for FQ-resistant E. coli carriage and was consistent for FQ exposures in the previous 3, 6, 9, or 12 months. Pulsed-field gel electrophoresis of FQ-resistant E. coli identified clonal spread of 1 strain among 16 residents. Loss (6 residents) or acquisition (7 residents) of FQ-resistant E. coli was documented and was associated with de novo colonization with genetically distinct strains. Unlike the case in the hospital setting, FQ-resistant E. coli carriage in long-term care facilities is associated with clonal spread.

        Cite This Article
    EID Maslow JN, Lee B, Lautenbach E. Fluoroquinolone-resistant Escherichia coli Carriage in Long-Term Care Facility. Emerg Infect Dis. 2005;11(6):889-894. https://dx.doi.org/10.3201/eid1106.041335
    AMA Maslow JN, Lee B, Lautenbach E. Fluoroquinolone-resistant Escherichia coli Carriage in Long-Term Care Facility. Emerging Infectious Diseases. 2005;11(6):889-894. doi:10.3201/eid1106.041335.
    APA Maslow, J. N., Lee, B., & Lautenbach, E. (2005). Fluoroquinolone-resistant Escherichia coli Carriage in Long-Term Care Facility. Emerging Infectious Diseases, 11(6), 889-894. https://dx.doi.org/10.3201/eid1106.041335.
  • Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci in Rural Communities, Western United States PDF Version [PDF - 243 KB - 9 pages]
    K. B. Stevenson et al.
        View Abstract

    The impact and prevalence of antimicrobial drug resistance in rural community healthcare settings is uncertain. Prospective surveillance in 51 rural hospitals in Idaho and Utah examined the epidemiologic features of clinical cases of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Thirty-two cases of VRE were reported; for 6, the patient had no prior healthcare exposure or coexisting condition. Among the 724 MRSA cases available for evaluation, 405 (56%) were healthcare-associated (HA-MRSA), and 319 (44%) were community-associated (CA-MRSA). The characteristics of HA-MRSA and CA-MRSA patients with coexisting factors were similar, which suggests community transmission of healthcare strains. CA-MRSA cases without coexisting factors, however, demonstrated features previously reported for community strains. MRSA infections were substantially more frequent than VRE in rural communities in the western United States. Based on epidemiologic criteria, a large proportion of MRSA cases were community-associated. CA-MRSA rates were predictive of institutional MRSA rates.

        Cite This Article
    EID Stevenson KB, Searle K, Stoddard G, Samore MH. Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci in Rural Communities, Western United States. Emerg Infect Dis. 2005;11(6):895-903. https://dx.doi.org/10.3201/eid1106.050156
    AMA Stevenson KB, Searle K, Stoddard G, et al. Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci in Rural Communities, Western United States. Emerging Infectious Diseases. 2005;11(6):895-903. doi:10.3201/eid1106.050156.
    APA Stevenson, K. B., Searle, K., Stoddard, G., & Samore, M. H. (2005). Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci in Rural Communities, Western United States. Emerging Infectious Diseases, 11(6), 895-903. https://dx.doi.org/10.3201/eid1106.050156.
  • Clinician Knowledge and Beliefs after Statewide Program to Promote Appropriate Antimicrobial Drug Use PDF Version [PDF - 216 KB - 8 pages]
    K. M. Kiang et al.
        View Abstract

    In 1999, Wisconsin initiated an educational campaign for primary care clinicians and the public to promote judicious antimicrobial drug use. We evaluated its impact on clinician knowledge and beliefs; Minnesota served as a control state. Results of pre- (1999) and post- (2002) campaign questionnaires indicated that Wisconsin clinicians perceived a significant decline in the proportion of patients requesting antimicrobial drugs (50% in 1999 to 30% in 2002; p<0.001) and in antimicrobial drug requests from parents for children (25% in 1999 to 20% in 2002; p = 0.004). Wisconsin clinicians were less influenced by nonpredictive clinical findings (purulent nasal discharge [p = 0.044], productive cough [p = 0.010]) in terms of antimicrobial drug prescribing. In 2002, clinicians from both states were less likely to recommend antimicrobial agent treatment for the adult case scenarios of viral respiratory illness. For the comparable pediatric case scenarios, only Wisconsin clinicians improved significantly from 1999 to 2002. Although clinicians in both states improved on several survey responses, greater overall improvement occurred in Wisconsin.

        Cite This Article
    EID Kiang KM, Kieke BA, Como-Sabetti K, Lynfield R, Besser RE, Belongia EA, et al. Clinician Knowledge and Beliefs after Statewide Program to Promote Appropriate Antimicrobial Drug Use. Emerg Infect Dis. 2005;11(6):904-911. https://dx.doi.org/10.3201/eid1106.050144
    AMA Kiang KM, Kieke BA, Como-Sabetti K, et al. Clinician Knowledge and Beliefs after Statewide Program to Promote Appropriate Antimicrobial Drug Use. Emerging Infectious Diseases. 2005;11(6):904-911. doi:10.3201/eid1106.050144.
    APA Kiang, K. M., Kieke, B. A., Como-Sabetti, K., Lynfield, R., Besser, R. E., & Belongia, E. A. (2005). Clinician Knowledge and Beliefs after Statewide Program to Promote Appropriate Antimicrobial Drug Use. Emerging Infectious Diseases, 11(6), 904-911. https://dx.doi.org/10.3201/eid1106.050144.
  • Impact of Statewide Program To Promote Appropriate Antimicrobial Drug Use PDF Version [PDF - 273 KB - 9 pages]
    E. A. Belongia et al.
        View Abstract

    The Wisconsin Antibiotic Resistance Network (WARN) was launched in 1999 to educate physicians and the public about judicious antimicrobial drug use. Public education included radio and television advertisements, posters, pamphlets, and presentations at childcare centers. Physician education included mailings, susceptibility reports, practice guidelines, satellite conferences, and presentations. We analyzed antimicrobial prescribing data for primary care physicians in Wisconsin and Minnesota (control state). Antimicrobial prescribing declined 19.8% in Minnesota and 20.4% in Wisconsin from 1998 to 2003. Prescribing by internists declined significantly more in Wisconsin than Minnesota, but the opposite was true for pediatricians. We conclude that the secular trend of declining antimicrobial drug use continued through 2003, but a large-scale educational program did not generate greater reductions in Wisconsin despite improved knowledge. State and local organizations should consider a balanced approach that includes limited statewide educational activities with increasing emphasis on local, provider-level interventions and policy development to promote careful antimicrobial drug use.

        Cite This Article
    EID Belongia EA, Knobloch M, Kieke BA, Davis JP, Janette C, Besser RE, et al. Impact of Statewide Program To Promote Appropriate Antimicrobial Drug Use. Emerg Infect Dis. 2005;11(6):912-920. https://dx.doi.org/10.3201/eid1106.050118
    AMA Belongia EA, Knobloch M, Kieke BA, et al. Impact of Statewide Program To Promote Appropriate Antimicrobial Drug Use. Emerging Infectious Diseases. 2005;11(6):912-920. doi:10.3201/eid1106.050118.
    APA Belongia, E. A., Knobloch, M., Kieke, B. A., Davis, J. P., Janette, C., & Besser, R. E. (2005). Impact of Statewide Program To Promote Appropriate Antimicrobial Drug Use. Emerging Infectious Diseases, 11(6), 912-920. https://dx.doi.org/10.3201/eid1106.050118.
  • Trypanosomiasis Relapse after Melarsoprol Therapy, Democratic Republic of Congo, 1982–2001 PDF Version [PDF - 182 KB - 7 pages]
    J. Pépin and B. Mpia
        View Abstract

    Recently, a high proportion of patients with late-stage Trypanosoma brucei gambiense trypanosomiasis, who had been treated with melarsoprol in some disease-endemic areas, subsequently relapsed. To determine whether the frequency of postmelarsoprol relapses increased over time, we reviewed data from 2,221 trypanosomiasis patients treated with melarsoprol during this period in Nioki, Democratic Republic of Congo, from 1982 to 2001. The frequency of relapses was 5.6%(31/553), 6.8%(35/512), 4.5%(18/398), 11.4%(34/299), and 5.0%(17/343) for those treated from 1982 to 1985, 1986 to 1989, 1990 to 1993, 1994 to 1997, and 1998 to 2001, respectively. The higher frequency of relapses in 1994 to 1997 was associated with an incremental dosage regimen of melarsoprol. In multivariate analysis, after adjustment for treatment regimen, sex, residence, and trypanosomes in cerebrospinal fluid, postmelarsoprol relapses did not increase in Nioki, perhaps because 1) little drug pressure exists; 2) subtherapeutic doses have rarely been administered; 3) little potential exists for the preferential transmission of melarsoprol-resistant strains.

        Cite This Article
    EID Pépin J, Mpia B. Trypanosomiasis Relapse after Melarsoprol Therapy, Democratic Republic of Congo, 1982–2001. Emerg Infect Dis. 2005;11(6):921-927. https://dx.doi.org/10.3201/eid1106.050036
    AMA Pépin J, Mpia B. Trypanosomiasis Relapse after Melarsoprol Therapy, Democratic Republic of Congo, 1982–2001. Emerging Infectious Diseases. 2005;11(6):921-927. doi:10.3201/eid1106.050036.
    APA Pépin, J., & Mpia, B. (2005). Trypanosomiasis Relapse after Melarsoprol Therapy, Democratic Republic of Congo, 1982–2001. Emerging Infectious Diseases, 11(6), 921-927. https://dx.doi.org/10.3201/eid1106.050036.

Dispatches

  • Methicillin-resistant Staphylococcus aureus in Community-acquired Skin Infections PDF Version [PDF - 47 KB - 3 pages]
    G. J. Moran et al.
        View Abstract

    Community-associated methicillin-resistant Staphylococcus aureus (MRSA) is the most common pathogen among patients with skin and soft tissue infections seeking treatment at a Los Angeles (USA) area emergency department. The proportion caused by MRSA increased from 29% in 2001 to 2002 to 64% in 2003 to 2004. No clinical or historical features reliably predict MRSA etiology.

        Cite This Article
    EID Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in Community-acquired Skin Infections. Emerg Infect Dis. 2005;11(6):928-930. https://dx.doi.org/10.3201/eid1106.040641
    AMA Moran GJ, Amii RN, Abrahamian FM, et al. Methicillin-resistant Staphylococcus aureus in Community-acquired Skin Infections. Emerging Infectious Diseases. 2005;11(6):928-930. doi:10.3201/eid1106.040641.
    APA Moran, G. J., Amii, R. N., Abrahamian, F. M., & Talan, D. A. (2005). Methicillin-resistant Staphylococcus aureus in Community-acquired Skin Infections. Emerging Infectious Diseases, 11(6), 928-930. https://dx.doi.org/10.3201/eid1106.040641.
  • Rifampicin Resistance in Tuberculosis Outbreak, London, England PDF Version [PDF - 249 KB - 4 pages]
    C. Jenkins et al.
        View Abstract

    Mycobacterium tuberculosis isolates cultured from 6 patients associated with an isoniazid-resistant M. tuberculosis outbreak acquired rifampicin resistance. The rpoB gene sequence showed that resistance was associated with rare mutations in each isolate. Three isolates had a mutation outside the rifampicin resistance–determining region.

        Cite This Article
    EID Jenkins C, Claxton AP, Shorten RJ, McHugh TD, Gillespie SH. Rifampicin Resistance in Tuberculosis Outbreak, London, England. Emerg Infect Dis. 2005;11(6):931-934. https://dx.doi.org/10.3201/eid1106.041262
    AMA Jenkins C, Claxton AP, Shorten RJ, et al. Rifampicin Resistance in Tuberculosis Outbreak, London, England. Emerging Infectious Diseases. 2005;11(6):931-934. doi:10.3201/eid1106.041262.
    APA Jenkins, C., Claxton, A. P., Shorten, R. J., McHugh, T. D., & Gillespie, S. H. (2005). Rifampicin Resistance in Tuberculosis Outbreak, London, England. Emerging Infectious Diseases, 11(6), 931-934. https://dx.doi.org/10.3201/eid1106.041262.
  • Dana Cole, Georgia Division of Public Health, Notifiable Disease Section, Department of Human Resources, 2 Peachtree Free-living Canada Geese and Antimicrobial Resistance PDF Version [PDF - 233 KB - 4 pages]
    D. Cole et al.
        View Abstract

    We describe antimicrobial resistance among Escherichia coli isolated from free-living Canada Geese in Georgia and North Carolina (USA). Resistance patterns are compared to those reported by the National Antimicrobial Resistance Monitoring System. Canada Geese may be vectors of antimicrobial resistance and resistance genes in agricultural environments.

        Cite This Article
    EID Cole D, Drum D, Stallknecht DE, White DG, Lee MD, Ayers S, et al. Dana Cole, Georgia Division of Public Health, Notifiable Disease Section, Department of Human Resources, 2 Peachtree Free-living Canada Geese and Antimicrobial Resistance. Emerg Infect Dis. 2005;11(6):935-938. https://dx.doi.org/10.3201/eid1106.040717
    AMA Cole D, Drum D, Stallknecht DE, et al. Dana Cole, Georgia Division of Public Health, Notifiable Disease Section, Department of Human Resources, 2 Peachtree Free-living Canada Geese and Antimicrobial Resistance. Emerging Infectious Diseases. 2005;11(6):935-938. doi:10.3201/eid1106.040717.
    APA Cole, D., Drum, D., Stallknecht, D. E., White, D. G., Lee, M. D., Ayers, S....Maurer, J. J. (2005). Dana Cole, Georgia Division of Public Health, Notifiable Disease Section, Department of Human Resources, 2 Peachtree Free-living Canada Geese and Antimicrobial Resistance. Emerging Infectious Diseases, 11(6), 935-938. https://dx.doi.org/10.3201/eid1106.040717.
  • Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–2003 PDF Version [PDF - 102 KB - 4 pages]
    S. Malhotra-Kumar et al.
        View Abstract

    We found a 13% macrolide resistance in 3,866 Streptococcus pyogenes isolated from tonsillopharyngitis patients; 59% macrolide-resistant isolates were distributed in 5 clones, suggesting the importance of both resistance gene transfer and clonal dissemination in the spread of these organisms. We also report one of the largest collections of telithromycin-resistant isolates.

        Cite This Article
    EID Malhotra-Kumar S, Lammens C, Chapelle S, Wijdooghe M, Piessens J, Van Herck K, et al. Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–2003. Emerg Infect Dis. 2005;11(6):939-942. https://dx.doi.org/10.3201/eid1106.041247
    AMA Malhotra-Kumar S, Lammens C, Chapelle S, et al. Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–2003. Emerging Infectious Diseases. 2005;11(6):939-942. doi:10.3201/eid1106.041247.
    APA Malhotra-Kumar, S., Lammens, C., Chapelle, S., Wijdooghe, M., Piessens, J., Van Herck, K....Goossens, H. (2005). Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–2003. Emerging Infectious Diseases, 11(6), 939-942. https://dx.doi.org/10.3201/eid1106.041247.
  • Hospitalization and Antimicrobial Resistance in Salmonella Outbreaks, 1984–2002 PDF Version [PDF - 131 KB - 4 pages]
    J. K. Varma et al.
        View Abstract

    Few studies have evaluated the health consequences of antimicrobial-resistant Salmonella strains associated with outbreaks. Among 32 outbreaks occurring in the United States from 1984 to 2002, 22% of 13,286 persons in 10 Salmonella-resistant outbreaks were hospitalized, compared with 8% of 2,194 persons in 22 outbreaks caused by pansusceptible Salmonella strains (p<0.01).

        Cite This Article
    EID Varma JK, Greene KD, Ovitt J, Barrett TJ, Medalla F, Angulo FJ, et al. Hospitalization and Antimicrobial Resistance in Salmonella Outbreaks, 1984–2002. Emerg Infect Dis. 2005;11(6):943-946. https://dx.doi.org/10.3201/eid1106.041231
    AMA Varma JK, Greene KD, Ovitt J, et al. Hospitalization and Antimicrobial Resistance in Salmonella Outbreaks, 1984–2002. Emerging Infectious Diseases. 2005;11(6):943-946. doi:10.3201/eid1106.041231.
    APA Varma, J. K., Greene, K. D., Ovitt, J., Barrett, T. J., Medalla, F., & Angulo, F. J. (2005). Hospitalization and Antimicrobial Resistance in Salmonella Outbreaks, 1984–2002. Emerging Infectious Diseases, 11(6), 943-946. https://dx.doi.org/10.3201/eid1106.041231.
  • Cephalosporin and Ciprofloxacin Resistance in Salmonella, Taiwan PDF Version [PDF - 191 KB - 4 pages]
    J. Yan et al.
        View Abstract

    We report the prevalence and characteristics of Salmonella strains resistant to ciprofloxacin and extended-spectrum cephalosporins in Taiwan from January to May 2004. All isolates resistant to extended-spectrum cephalosporins carried blaCMY-2, and all ciprofloxacin-resistant Salmonella enterica serotype Choleraesuis isolates were genetically related.

        Cite This Article
    EID Yan J, Chiou C, Lauderdale T, Tsai S, Wu J. Cephalosporin and Ciprofloxacin Resistance in Salmonella, Taiwan. Emerg Infect Dis. 2005;11(6):947-950. https://dx.doi.org/10.3201/eid1106.041153
    AMA Yan J, Chiou C, Lauderdale T, et al. Cephalosporin and Ciprofloxacin Resistance in Salmonella, Taiwan. Emerging Infectious Diseases. 2005;11(6):947-950. doi:10.3201/eid1106.041153.
    APA Yan, J., Chiou, C., Lauderdale, T., Tsai, S., & Wu, J. (2005). Cephalosporin and Ciprofloxacin Resistance in Salmonella, Taiwan. Emerging Infectious Diseases, 11(6), 947-950. https://dx.doi.org/10.3201/eid1106.041153.
  • Global Spread of Multiple Aminoglycoside Resistance Genes PDF Version [PDF - 68 KB - 3 pages]
    K. Yamane et al.
        View Abstract

    Emergence of the newly identified 16S rRNA methylases RmtA, RmtB, and ArmA in pathogenic gram-negative bacilli has been a growing concern. ArmA, which had been identified exclusively in Europe, was also found in several gram-negative pathogenic bacilli isolated in Japan, suggesting global dissemination of hazardous multiple aminoglycoside resistance genes.

        Cite This Article
    EID Yamane K, Wachino J, Doi Y, Kurokawa H, Arakawa Y. Global Spread of Multiple Aminoglycoside Resistance Genes. Emerg Infect Dis. 2005;11(6):951-953. https://dx.doi.org/10.3201/eid1106.040924
    AMA Yamane K, Wachino J, Doi Y, et al. Global Spread of Multiple Aminoglycoside Resistance Genes. Emerging Infectious Diseases. 2005;11(6):951-953. doi:10.3201/eid1106.040924.
    APA Yamane, K., Wachino, J., Doi, Y., Kurokawa, H., & Arakawa, Y. (2005). Global Spread of Multiple Aminoglycoside Resistance Genes. Emerging Infectious Diseases, 11(6), 951-953. https://dx.doi.org/10.3201/eid1106.040924.
  • armA and Aminoglycoside Resistance in Escherichia coli PDF Version [PDF - 132 KB - 3 pages]
    B. González-Zorn et al.
        View Abstract

    We report armA in an Escherichia coli pig isolate from Spain. The resistance gene was borne by self-transferable IncN plasmid pMUR050. Molecular analysis of the plasmid and of the armA locus confirmed the spread of this resistance determinant.

        Cite This Article
    EID González-Zorn B, Teshager T, Casas M, Porrero MC, Moreno MA, Courvalin P, et al. armA and Aminoglycoside Resistance in Escherichia coli. Emerg Infect Dis. 2005;11(6):954-956. https://dx.doi.org/10.3201/eid1106.040553
    AMA González-Zorn B, Teshager T, Casas M, et al. armA and Aminoglycoside Resistance in Escherichia coli. Emerging Infectious Diseases. 2005;11(6):954-956. doi:10.3201/eid1106.040553.
    APA González-Zorn, B., Teshager, T., Casas, M., Porrero, M. C., Moreno, M. A., Courvalin, P....Domínguez, L. (2005). armA and Aminoglycoside Resistance in Escherichia coli. Emerging Infectious Diseases, 11(6), 954-956. https://dx.doi.org/10.3201/eid1106.040553.
  • Tuberculosis due to Resistant Haarlem Strain, Tunisia PDF Version [PDF - 187 KB - 5 pages]
    H. Mardassi et al.
        View Abstract

    Multidrug-resistant tuberculosis was diagnosed in 21 HIV-negative, nonhospitalized male patients residing in northern Tunisia. A detailed investigation showed accelerated transmission of a Mycobacterium tuberculosis clone of the Haarlem type in 90% of all patients. This finding highlights the epidemic potential of this prevalent genotype.

        Cite This Article
    EID Mardassi H, Namouchi A, Haltiti R, Zarrouk M, Mhenni B, Karboul A, et al. Tuberculosis due to Resistant Haarlem Strain, Tunisia. Emerg Infect Dis. 2005;11(6):957-961. https://dx.doi.org/10.3201/eid1106.041365
    AMA Mardassi H, Namouchi A, Haltiti R, et al. Tuberculosis due to Resistant Haarlem Strain, Tunisia. Emerging Infectious Diseases. 2005;11(6):957-961. doi:10.3201/eid1106.041365.
    APA Mardassi, H., Namouchi, A., Haltiti, R., Zarrouk, M., Mhenni, B., Karboul, A....Dellagi, K. (2005). Tuberculosis due to Resistant Haarlem Strain, Tunisia. Emerging Infectious Diseases, 11(6), 957-961. https://dx.doi.org/10.3201/eid1106.041365.
  • Community-associated Methicillin-resistant Staphylococcus aureus, Switzerland PDF Version [PDF - 131 KB - 4 pages]
    S. Harbarth et al.
        View Abstract

    Two case-control studies evaluated the prevalence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) carriage at hospital admission and characteristics of patients with CA-MRSA. Among 14,253 patients, CA-MRSA prevalence was 0.9/1,000 admissions. Although 5 CA-MRSA isolates contained Panton-Valentine leukocidin, only 1 patient had a previous skin infection. No easily modifiable risk factor for CA-MRSA was identified.

        Cite This Article
    EID Harbarth S, François P, Schrenzel J, Fankhauser-Rodriguez C, Hugonnet S, Koessler T, et al. Community-associated Methicillin-resistant Staphylococcus aureus, Switzerland. Emerg Infect Dis. 2005;11(6):962-965. https://dx.doi.org/10.3201/eid1106.041308
    AMA Harbarth S, François P, Schrenzel J, et al. Community-associated Methicillin-resistant Staphylococcus aureus, Switzerland. Emerging Infectious Diseases. 2005;11(6):962-965. doi:10.3201/eid1106.041308.
    APA Harbarth, S., François, P., Schrenzel, J., Fankhauser-Rodriguez, C., Hugonnet, S., Koessler, T....Pittet, D. (2005). Community-associated Methicillin-resistant Staphylococcus aureus, Switzerland. Emerging Infectious Diseases, 11(6), 962-965. https://dx.doi.org/10.3201/eid1106.041308.
  • Community-associated Methicillin-resistant Staphylococcus aureus in Pediatric Patients PDF Version [PDF - 57 KB - 3 pages]
    T. J. Ochoa et al.
        View Abstract

    Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections increased from 2000 to 2003 in hospitalized pediatric patients in Houston. CA-MRSA was associated with greater illness than was infection with methicillin-susceptible strains. Children with CA-MRSA were younger and mostly African American. Of MRSA isolates, 4.5% had the inducible macrolide-lincosamide-streptogramin B phenotype.

        Cite This Article
    EID Ochoa TJ, Mohr J, Wanger A, Murphy JR, Heresi GP. Community-associated Methicillin-resistant Staphylococcus aureus in Pediatric Patients. Emerg Infect Dis. 2005;11(6):966-968. https://dx.doi.org/10.3201/eid1106.050142
    AMA Ochoa TJ, Mohr J, Wanger A, et al. Community-associated Methicillin-resistant Staphylococcus aureus in Pediatric Patients. Emerging Infectious Diseases. 2005;11(6):966-968. doi:10.3201/eid1106.050142.
    APA Ochoa, T. J., Mohr, J., Wanger, A., Murphy, J. R., & Heresi, G. P. (2005). Community-associated Methicillin-resistant Staphylococcus aureus in Pediatric Patients. Emerging Infectious Diseases, 11(6), 966-968. https://dx.doi.org/10.3201/eid1106.050142.
  • Erythromycin-nonsusceptible Streptococcus pneumoniae in Children, 1999–2001 PDF Version [PDF - 110 KB - 4 pages]
    M. McEllistrem et al.
        View Abstract

    After increasing from 1995 to 1999, invasive erythromycin-nonsusceptible Streptococcus pneumoniae rates per 100,000 decreased 53.6% in children from Baltimore, Maryland (US), from 1999 to 2001, which was partially attributed to strains related to the mefE-carrying England14-9 clone. The decline in infection rates was likely due to the pneumococcal 7-valent conjugate vaccine.

        Cite This Article
    EID McEllistrem M, Adams JM, Shutt K, Sanza LT, Facklam RR, Whitney CG, et al. Erythromycin-nonsusceptible Streptococcus pneumoniae in Children, 1999–2001. Emerg Infect Dis. 2005;11(6):969-972. https://dx.doi.org/10.3201/eid1106.050119
    AMA McEllistrem M, Adams JM, Shutt K, et al. Erythromycin-nonsusceptible Streptococcus pneumoniae in Children, 1999–2001. Emerging Infectious Diseases. 2005;11(6):969-972. doi:10.3201/eid1106.050119.
    APA McEllistrem, M., Adams, J. M., Shutt, K., Sanza, L. T., Facklam, R. R., Whitney, C. G....Harrison, L. H. (2005). Erythromycin-nonsusceptible Streptococcus pneumoniae in Children, 1999–2001. Emerging Infectious Diseases, 11(6), 969-972. https://dx.doi.org/10.3201/eid1106.050119.
  • Community-acquired Methicillin-resistant Staphylococcus aureus, Uruguay PDF Version [PDF - 98 KB - 4 pages]
    X. Ma et al.
        View Abstract

    A novel, methicillin-resistant Staphylococcus aureus clone (Uruguay clone) with a non–multidrug-resistant phenotype caused a large outbreak, including 7 deaths, in Montevideo, Uruguay. The clone was distinct from the highly virulent community clone represented by strain MW2, although both clones carried Panton-Valentine leukocidin gene and cna gene.

        Cite This Article
    EID Ma X, Galiana A, Pedreira W, Mowszowicz M, Christophersen I, Machiavello S, et al. Community-acquired Methicillin-resistant Staphylococcus aureus, Uruguay. Emerg Infect Dis. 2005;11(6):973-976. https://dx.doi.org/10.3201/eid1106.041059
    AMA Ma X, Galiana A, Pedreira W, et al. Community-acquired Methicillin-resistant Staphylococcus aureus, Uruguay. Emerging Infectious Diseases. 2005;11(6):973-976. doi:10.3201/eid1106.041059.
    APA Ma, X., Galiana, A., Pedreira, W., Mowszowicz, M., Christophersen, I., Machiavello, S....Hiramatsu, K. (2005). Community-acquired Methicillin-resistant Staphylococcus aureus, Uruguay. Emerging Infectious Diseases, 11(6), 973-976. https://dx.doi.org/10.3201/eid1106.041059.
  • Rifampin-resistant Meningococcal Disease PDF Version [PDF - 70 KB - 3 pages]
    J. Rainbow et al.
        View Abstract

    Rifampin-resistant meningococcal disease occurred in a child who had completed rifampin chemoprophylaxis for exposure to a sibling with meningococcemia. Susceptibility testing of 331 case isolates found only 1 other case of rifampin-resistant disease in Minnesota, USA, during 11 years of statewide surveillance. Point mutations in the RNA polymerase β subunit (rpoB) gene were found in isolates from each rifampin-resistant case-patient.

        Cite This Article
    EID Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R, et al. Rifampin-resistant Meningococcal Disease. Emerg Infect Dis. 2005;11(6):977-979. https://dx.doi.org/10.3201/eid1106.050143
    AMA Rainbow J, Cebelinski E, Bartkus J, et al. Rifampin-resistant Meningococcal Disease. Emerging Infectious Diseases. 2005;11(6):977-979. doi:10.3201/eid1106.050143.
    APA Rainbow, J., Cebelinski, E., Bartkus, J., Glennen, A., Boxrud, D., & Lynfield, R. (2005). Rifampin-resistant Meningococcal Disease. Emerging Infectious Diseases, 11(6), 977-979. https://dx.doi.org/10.3201/eid1106.050143.

Letters

  • Diversification in Salmonella Typhimurium DT104 PDF Version [PDF - 26 KB - 2 pages]
    J. Threlfall et al.
            Cite This Article
    EID Threlfall J, Hopkins KL, Ward LR. Diversification in Salmonella Typhimurium DT104. Emerg Infect Dis. 2005;11(6):980-981. https://dx.doi.org/10.3201/eid1106.050100
    AMA Threlfall J, Hopkins KL, Ward LR. Diversification in Salmonella Typhimurium DT104. Emerging Infectious Diseases. 2005;11(6):980-981. doi:10.3201/eid1106.050100.
    APA Threlfall, J., Hopkins, K. L., & Ward, L. R. (2005). Diversification in Salmonella Typhimurium DT104. Emerging Infectious Diseases, 11(6), 980-981. https://dx.doi.org/10.3201/eid1106.050100.
  • Extended-spectrum β-Lactamase-producing Flora in Healthy Persons PDF Version [PDF - 37 KB - 2 pages]
    C. Rodrigues et al.
            Cite This Article
    EID Rodrigues C, Shukla U, Jog S, Mehta A. Extended-spectrum β-Lactamase-producing Flora in Healthy Persons. Emerg Infect Dis. 2005;11(6):981-982. https://dx.doi.org/10.3201/eid1106.041111
    AMA Rodrigues C, Shukla U, Jog S, et al. Extended-spectrum β-Lactamase-producing Flora in Healthy Persons. Emerging Infectious Diseases. 2005;11(6):981-982. doi:10.3201/eid1106.041111.
    APA Rodrigues, C., Shukla, U., Jog, S., & Mehta, A. (2005). Extended-spectrum β-Lactamase-producing Flora in Healthy Persons. Emerging Infectious Diseases, 11(6), 981-982. https://dx.doi.org/10.3201/eid1106.041111.
  • Measuring Impact of Antimicrobial Resistance PDF Version [PDF - 37 KB - 2 pages]
    M. Roghmann et al.
            Cite This Article
    EID Roghmann M, Bradham DD, Zhan M, Fridkin SK, Perl TM. Measuring Impact of Antimicrobial Resistance. Emerg Infect Dis. 2005;11(6):982-983. https://dx.doi.org/10.3201/eid1106.041220
    AMA Roghmann M, Bradham DD, Zhan M, et al. Measuring Impact of Antimicrobial Resistance. Emerging Infectious Diseases. 2005;11(6):982-983. doi:10.3201/eid1106.041220.
    APA Roghmann, M., Bradham, D. D., Zhan, M., Fridkin, S. K., & Perl, T. M. (2005). Measuring Impact of Antimicrobial Resistance. Emerging Infectious Diseases, 11(6), 982-983. https://dx.doi.org/10.3201/eid1106.041220.
  • Antimicrobial Resistance in Campylobacter PDF Version [PDF - 24 KB - 2 pages]
    L. Cox et al.
            Cite This Article
    EID Cox L, Copeland D, Vaughn M. Antimicrobial Resistance in Campylobacter. Emerg Infect Dis. 2005;11(6):983-984. https://dx.doi.org/10.3201/eid1106.040689
    AMA Cox L, Copeland D, Vaughn M. Antimicrobial Resistance in Campylobacter. Emerging Infectious Diseases. 2005;11(6):983-984. doi:10.3201/eid1106.040689.
    APA Cox, L., Copeland, D., & Vaughn, M. (2005). Antimicrobial Resistance in Campylobacter. Emerging Infectious Diseases, 11(6), 983-984. https://dx.doi.org/10.3201/eid1106.040689.
  • Quinolone Safety and Efficacy PDF Version [PDF - 122 KB - 3 pages]
    S. Bellomo
            Cite This Article
    EID Bellomo S. Quinolone Safety and Efficacy. Emerg Infect Dis. 2005;11(6):985-987. https://dx.doi.org/10.3201/eid1106.040740
    AMA Bellomo S. Quinolone Safety and Efficacy. Emerging Infectious Diseases. 2005;11(6):985-987. doi:10.3201/eid1106.040740.
    APA Bellomo, S. (2005). Quinolone Safety and Efficacy. Emerging Infectious Diseases, 11(6), 985-987. https://dx.doi.org/10.3201/eid1106.040740.

About the Cover

  • Drugs, Microbes, and Antimicrobial Resistance PDF Version [PDF - 110 KB - 2 pages]
    P. Potter
            Cite This Article
    EID Potter P. Drugs, Microbes, and Antimicrobial Resistance. Emerg Infect Dis. 2005;11(6):988-989. https://dx.doi.org/10.3201/eid1106.AC1106
    AMA Potter P. Drugs, Microbes, and Antimicrobial Resistance. Emerging Infectious Diseases. 2005;11(6):988-989. doi:10.3201/eid1106.AC1106.
    APA Potter, P. (2005). Drugs, Microbes, and Antimicrobial Resistance. Emerging Infectious Diseases, 11(6), 988-989. https://dx.doi.org/10.3201/eid1106.AC1106.

Corrections

  • Correction: Vol. 11, No. 5 PDF Version [PDF - 13 KB - 1 page]
            Cite This Article
    EID Correction: Vol. 11, No. 5. Emerg Infect Dis. 2005;11(6):976. https://dx.doi.org/10.3201/eid1106.C11106
    AMA Correction: Vol. 11, No. 5. Emerging Infectious Diseases. 2005;11(6):976. doi:10.3201/eid1106.C11106.
    APA (2005). Correction: Vol. 11, No. 5. Emerging Infectious Diseases, 11(6), 976. https://dx.doi.org/10.3201/eid1106.C11106.
  • Correction: Vol. 11, No. 5 PDF Version [PDF - 13 KB - 1 page]
            Cite This Article
    EID Correction: Vol. 11, No. 5. Emerg Infect Dis. 2005;11(6):976. https://dx.doi.org/10.3201/eid1106.C21106
    AMA Correction: Vol. 11, No. 5. Emerging Infectious Diseases. 2005;11(6):976. doi:10.3201/eid1106.C21106.
    APA (2005). Correction: Vol. 11, No. 5. Emerging Infectious Diseases, 11(6), 976. https://dx.doi.org/10.3201/eid1106.C21106.
  • Correction: Vol. 11, No. 5 PDF Version [PDF - 13 KB - 1 page]
            Cite This Article
    EID Correction: Vol. 11, No. 5. Emerg Infect Dis. 2005;11(6):976. https://dx.doi.org/10.3201/eid1106.C31106
    AMA Correction: Vol. 11, No. 5. Emerging Infectious Diseases. 2005;11(6):976. doi:10.3201/eid1106.C31106.
    APA (2005). Correction: Vol. 11, No. 5. Emerging Infectious Diseases, 11(6), 976. https://dx.doi.org/10.3201/eid1106.C31106.
TOP